Sharemaestro Newsreel

IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors

IQVIA Holdings Inc. (IQV) stock fell by 3.95% on Thursday, closing at $237.79. This underperformance occurred despite a generally favorable trading session where the S&P 500 Index and Dow Jones Industrial Average both saw gains. The decline ended a five-day winning streak for IQVIA.

ICON to Deploy Claude AI Across Clinical Trial Lifecycle

ICON plc has partnered with Anthropic to integrate Claude AI across the clinical trial lifecycle, leveraging AI to improve study planning, risk detection, and protocol optimization. This multi-year collaboration aims to accelerate innovation in clinical development by combining ICON's expertise with Anthropic's frontier AI …

Argus Research Adjusts Quest Diagnostics Price Target to $260 From $225, Maintains Buy Rating

Argus Research has increased its price target for Quest Diagnostics (DGX) to $260 from $225, while reiterating a Buy rating on the stock. This adjustment reflects a positive outlook on the company's future performance. The article also notes other recent analyst adjustments for Quest …

RadNet subsidiary DeepHealth wins FDA clearance for AI-powered breast ultrasound tool

DeepHealth, a RadNet subsidiary, has received FDA 510(k) clearance for its AI-powered breast ultrasound tool designed for lesion detection and characterization. The product boasts high accuracy and improved cancer detection sensitivity, with a commercial rollout beginning immediately in the US. Deployment is planned across …

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in …

First Trust entities disclose 10.1M-share NeoGenomics (NEO) position in 13G

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have jointly filed a Schedule 13G, disclosing beneficial ownership of 10,113,261 shares of NeoGenomics (NEo), which represents 7.77% of the class. First Trust Advisors L.P. and The Charger Corporation hold shared voting …

Quest Diagnostics Growth Drivers Investors Should Watch Now in 2026

Quest Diagnostics (DGX) is propelled by broad testing demand, expanded payer access, advanced diagnostics, and strategic partnerships, supporting revenue growth in 2026. The company's base business benefits from physician, hospital, and consumer channels, while advanced diagnostics in multiple health areas and acquisitions contribute significantly. …

Guardant Health Inc (GH) pullback contrasts with active weekly trend

The healthcare diagnostics stock weakened over the latest week, but the longer 12-week performance and trend screen leave the setup mixed.

Veracyte: Q2 Earnings Snapshot

Veracyte Inc. (VCYT) reported robust second-quarter results, with profits reaching $25.5 million, or 31 cents per share. After adjustments, earnings were 54 cents per share, surpassing Wall Street's expectation of 43 cents. The molecular diagnostic company also exceeded revenue forecasts, posting $150.3 million against …

PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG

This article announces that QIAGEN N.V. has published a voting rights notification in accordance with § 40 Abs. 1 WpHG, as informed by the AFM on July 29, 2026. The notification details various share and voting rights distributions related to Goldman Sachs Group Inc., …

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates

Castle Biosciences, Inc. (CSTL) reported a Q2 loss of $0.07 per share, significantly beating the Zacks Consensus Estimate loss of $0.44 due to non-recurring items. The company also surpassed revenue estimates with $103.55 million, an 18.61% beat, continuing a trend of outperforming revenue expectations …

Tempus AI buys Personalis for $1.7B as digital health M&A su

Tempus AI's acquisition of Personalis for $1.7 billion signals a significant consolidation trend in health-tech amid a surge in M&A and venture capital activities, with $7.4 billion in funding during the first half of 2026. This trend is reshaping vendor choices for health system …

Earnings Beat: OPKO Health, Inc. (NASDAQ:OPK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

OPKO Health, Inc. recently reported a significant earnings beat, surpassing analyst revenue and statutory EPS forecasts. Following these results, analysts have raised their revenue and EPS estimates for the company's future performance, suggesting a more optimistic outlook. The revised forecasts indicate a positive sentiment …

Earnings call transcript: Labcorp tops Q2 2026 estimates, lifts full-year outlook

Labcorp exceeded Q2 2026 estimates with strong revenue and adjusted EPS, leading to a lifted full-year outlook. The company reported adjusted EPS of $4.99 and revenue of $3.73 billion, driven by solid organic growth, margin expansion, and strong performance in specialty testing and biopharma …

Adaptive Biotechnologies stock hits 52-week high at 23.25 USD

Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $23.25, reflecting a significant 120.31% increase over the past year. Despite its robust revenue growth of 56% over the last twelve months, InvestingPro analytical data suggests the stock might be overvalued. Recent Q2 results showed …

Natera executive chairman sells $447k in shares

Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NASDAQ:NTRA), sold 1,718 shares for $447,523 to cover tax obligations related to restricted stock units. This sale comes as Natera shares have risen 80% over the past year, though InvestingPro suggests the stock is overvalued. …

Natera, Inc. (NTRA) CFO disposes of 5,064 shares in 10b5-1 trades

Natera, Inc.'s CFO, Brophy Michael Burkes, sold a total of 5,064 shares of common stock between July 27-29, 2026, through open-market transactions. These sales, executed under a Rule 10b5-1 trading plan adopted in 2025, included shares sold to cover tax withholding obligations related to …

Medpace Holdings President & CEO Trades $4.35M In Company Stock

Medpace Holdings's President & CEO, August J Troendle, sold 7,238 shares of company stock worth $4.35 million on July 29, 2026, according to an SEC filing. Despite this insider sale, the company reported strong revenue growth of 17.24% for the quarter ending June 30, …

Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%

Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2026 sales of $190.7 million, falling short of analyst estimates, and a non-GAAP loss of $0.25 per share, significantly below consensus. The company also lowered its full-year revenue guidance to $780 million at the midpoint from an earlier $870 …

CareDx, Inc. 2Q 2026: Revenue $131.95M, EPS $2.07— 10-Q Summary

CareDx, Inc. (CDNA) reported strong second-quarter 2026 results with revenue of $131.95 million and diluted EPS of $2.07. This performance was significantly boosted by higher testing services volume, prior-period collections, and a one-time gain of approximately $113 million from the sale of its lab …

Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat

Veracyte, Inc. (VCYT) saw its shares advance significantly during Q2 2026 due to a strong earnings beat and raised full-year guidance, driven by double-digit volume growth in its Decipher test and improved Afirma performance. Meridian Small Cap Growth Fund highlighted VCYT as a key …

Labcorp (LH) Reports Q2 Earnings: What Key Metrics Have to Say

Labcorp Holdings (LH) reported $3.73 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.8%. EPS of $4.99 for the same period compares to $4.35 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.72 …

OPKO Health FY2026 EPS Estimate Increased by HC Wainwright

HC Wainwright has increased its FY2026 EPS estimate for OPKO Health to a loss of $0.23 per share from $0.30, while maintaining a "Buy" rating. This upgrade follows OPKO's recent quarterly results, which surpassed expectations with a $0.01-per-share loss against an estimated $0.08 loss …

ICON (ICLR) Is Up 6.5% After Reaffirming 2026 Outlook And Announcing Anthropic AI Deal – Has The Bull Case Changed?

William Blair Initiates Icon PLC(ICLR.US) With Buy Rating

William Blair has initiated coverage on Icon PLC (ICLR.US) with a Buy rating. This indicates a positive outlook from the investment firm regarding the company's stock performance.

Labcorp (NYSE:LH) Reports Q2 CY2026 In Line With Expectations

Labcorp (NYSE:LH) reported Q2 CY2026 results, meeting revenue expectations with $3.73 billion and beating adjusted EPS estimates at $4.99 per share. The company slightly increased its full-year revenue and Adjusted EPS guidance, demonstrating continued momentum despite a slight post-earnings stock dip. While long-term revenue …

Labcorp raises annual profit forecast on strong testing demand

By Sahil Pandey July 30 (Reuters) - Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, ‌as steady demand for diagnostic testing and growth in ‌its drug-development services business boosted performance. Shares of the company fell about 6% …

Icon PLC (ICLR) Shares Fall 7.1% -- What GF Score of 88 Tells In

Icon PLC (ICLR) shares recently fell 7.1% to $165.53, yet the company holds a strong GF Score of 88/100, indicating solid fundamentals and growth potential. Despite a high historical P/E, ICLR is considered "modestly undervalued" by GuruFocus, with a GF Value of $227.59, suggesting …

Deutsche Bank Downgrades Option Care Health to Hold From Buy, Adjusts PT to $24 From $26

Deutsche Bank has downgraded Option Care Health (OPCH) from a "Buy" rating to "Hold" and reduced its price target from $26 to $24. This action indicates a revised outlook on the stock's performance. Previously, Stephens also downgraded Option Care to "Equal Weight" from "Overweight" …

XWELL Inc. Q3 2023 Earnings: Losses Widen Sharply, Stock Declines - Dividend Growth Analysis

Prenetics (NASDAQ: PRE) updates Hong Kong risk, Bitcoin treasury

Prenetics (NASDAQ: PRE) has filed an amendment to its 2025 annual report, clarifying its holding-company structure, intra-group cash flows, non-IFRS indicators, and risks associated with Hong Kong and the PRC. The company also disclosed substantial net losses from 2023-2025 due to marketing investments for …

IQVIA Stock Climbs 25% On A 5-Day Winning Streak

IQVIA (IQV) stock has experienced a significant surge, climbing 25% over five consecutive trading days, adding $8.1 billion to its market value. This strong performance, which outpaced the S&P 500's decline during the same period, is supported by the company's slightly faster-than-market revenue growth …

Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics

A national Health Trends® study by Quest Diagnostics and Hologic, Inc. found that women testing positive for bacterial vaginosis (BV) were over three times more likely to also have non-viral sexually transmitted infections (STIs). The study, which analyzed data from 1.5 million women between …

Bacterial vaginosis patients were over 3x more likely to have an STI

A national study by Quest Diagnostics and Hologic, analyzing data from over 1.5 million U.S. women, found that 12% of women positive for bacterial vaginosis (BV) also had at least one non-viral sexually transmitted infection (STI), compared to 3.8% of BV-negative women. BV positivity …

Thermo Fisher Scientific Inc (TMO) pairs a 6.7% week with elevated volume

The diagnostics and research supplier is extending a three-month advance, though the trend screen has not turned active.

Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld …